Abstract: Disclosed are composite compositions of B vitamins and C vitamins and the use of same in the preparation of a drug or health food for treating and/or preventing gastrointestinal conditions diseases related to deficiency of the gastrointestinal system motility. The composition comprises a vitamin B composition or an analogue or a derivative thereof and a vitamin C or an analogue or a derivative thereof.

Abstract: The present invention provides extended release compositions comprising neuregulin for preventing, treating or delaying various diseases or disorders. The present invention also provides methods for preventing, treating or delaying various diseases or disorders by extended release of neuregulin.

Abstract: A use of a vitamin composition in preparing a drug for preventing, treating, or delaying Alzheimer's disease. The composition comprises a B vitamins composition or an analog or derivative thereof, vitamin C or an analog or derivative thereof, or a combination of a B vitamins composition or an analog or derivative thereof with vitamin C or an analog or derivative thereof.

Abstract: Disclosed are composite compositions of B vitamins and C vitamins and the use of same in the preparation of a drug or health food for treating and/or preventing gastrointestinal conditions diseases related to deficiency of the gastrointestinal system motility. The composition comprises a vitamin B composition or an analogue or a derivative thereof and a vitamin C or an analogue or a derivative thereof.

Abstract: Disclosed are composite compositions of B vitamins and C vitamins and the use of same in the preparation of a drug or health food for treating and/or preventing gastrointestinal conditions diseases related to deficiency of the gastrointestinal system motility. The composition comprises a vitamin B composition or an analogue or a derivative thereof and a vitamin C or an analogue or a derivative thereof.

Abstract: A method for preventing, treating or delaying myocardial damage in a mammal using neuregulin and a composition. An administration method for, an administration frequency of and an administration dosage of a pharmaceutical formulation or composition for reducing myocardial damage. It can be proved in a rat myocardial damage model that neuregulin can improve the cardiac function after myocardial infarction, suggesting that neuregulin can be used for preventing, treating, or delaying myocardial infarction damage.

Abstract: The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin.

Abstract: The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.

Abstract: The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.

Abstract: The present invention provides the use of neuregulin protein for the preparation of medication for preventing, treating or delaying heart failure in humans and methods for preventing, treating or delaying heart failure in humans using said medication.

Abstract: The present invention relates to a composition of multivitamin vitamin B-C, particularly a composition of vitamin B-C for stimulating gastrointestinal (GI) system motility. The composition is suitable for preventing and/or treating conditions or diseases associated with insufficient GI motility.

Abstract: The present invention provides a pharmaceutical preparation for treating a cardiovascular disease. Particularly, the present invention provides a formula of a neuregulin pharmaceutical preparation. The formula consist of neuregulin polypeptide, a buffer, a stabilizer, an excipient, a salt, and another component, can ensure the long-term stability of the neuregulin polypeptide, and can be used for treating a heart failure patient or a patient in a risk of the heart failure.

Abstract: Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.

Abstract: Disclosed are uses of neuregulin in the preparation of medicines for preventing, treating or delaying ventricular arrhythmia of a human being, and pharmaceutical preparations that comprise the neuregulin and are used for preventing, treating or delaying the ventricular arrhythmia.

Abstract: The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to neukinase. In other aspects, the present invention further provides methods of identifying predisposition to cardiac dysfunction, methods of detecting the presence of neukinase, neukinase nucleic acid, methods of screening for agents which affect neukinase activity, and methods of modulating neukinase activity.

Abstract: The present invention provides polypeptide variants of neuregulin-1? (NRG-1?) that have enhanced or decreased binding affinity to ErbB3 and/or ErbB4. The invention also provides methods of screening and producing polypeptide variants of NRG-1? and methods of using polypeptide variants of NRG-1? for treating diseases.

Abstract: The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.

Abstract: The present disclosure relates to an electric orifice cleaning brush including a brush head, a brush head mounting platform onto which the brush head is detachably mounted, and a motor holder for supporting the brush head mounting platform and accommodating a motor. The brush head includes a bristle implanting portion in the shape of a truncated cone and comprising a center region and bristles formed in bristle bindles. The bristle bindles are disposed outside the center region of the bristle implanting portion and are radially distributed in an evenly spaced manner. By means of the present disclosure, a complete cleaning of an orifice of a human body can be achieved, and damages to the orifice can be avoided.

Abstract: Methods for arresting or inhibiting cell growth, particularly cancer cell growth, comprising preventing or reducing ErbB-2/ErbB-3 heterodimer formation, or interfering with ErbB-2/ErbB-3 heterodimer conformation in a cell and agents which prevent or reduce ErbB-2/ErbB-3 heterodimer formation or interface with ErbB-2/ErbB-3 heterodimer conformation in a cell thereby arresting or inhibiting the growth of the cell.

Abstract: The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.